Search Result

Results for "

proliferation rates

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (1) Apoptosis (3) Bacterial (2) CD73 (1) DNA/RNA Synthesis (1) Drug Derivative (2) Endogenous Metabolite (2) ERK (1) Ferroptosis (1) Glutathione Peroxidase (1) GnRH Receptor (1) Histone Demethylase (1) Interleukin Related (1) JAK (1) Microtubule/Tubulin (2) PARP (1) Reactive Oxygen Species (2) SARS-CoV (1) TNF Receptor (1) Topoisomerase (1) VEGFR (2)
By Research Areas:	Cancer (16) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (3)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160927

Docosahexaenoyl Serinol	Drug Derivative	Cancer
Docosahexaenoyl Serinol (Compound 1) inhibits proliferation of lung cancaer cells A549, with 77.4% inhibition rate at 3 μM .

HY-106647

Abacavir hydroxyacetate	Interleukin Related	Inflammation/Immunology
Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. Abacavir hydroxyacetate reduces proliferation rate of skin in psoriasis as an immune modulator. Abacavir hydroxyacetate can be used for the research of inflammatory skin problems .

HY-W800162

VEGFR-2-IN-37	VEGFR	Cancer
VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .

HY-145881

Elongation factor P-IN-2	Bacterial	Infection
Elongation factor P-IN-2 is a potent inhibitor elongation factor P (EFP). Elongation factor P-IN-2 is a β-lysine derivative compound. Elongation factor P-IN-2 affects the proliferation rates of E. coli .

HY-145880

Elongation factor P-IN-1	Bacterial	Infection
Elongation factor P-IN-1 is a potent inhibitor elongation factor P (EFP). Elongation factor P-IN-1 is a β-lysine derivative compound. Elongation factor P-IN-1 affects the proliferation rates of E. coli .

HY-P10616

Salusin-α	Endogenous Metabolite	Cardiovascular Disease
Salusin-α is an endogenous bioactive peptide with hemodynamic and cell proliferation activities. Salusin-α can stimulate the proliferation of quiescent vascular smooth muscle cells (VSMCs) and fibroblasts, leading to a rapid and significant decrease in blood pressure and heart rate, but its effect is weaker than that of Salusin-β (HY-P10617). Salusin-α has potential application value in cardiovascular disease research .

HY-168011

GPX4-IN-14	Ferroptosis Glutathione Peroxidase Reactive Oxygen Species	Cancer
GPX4-IN-14 (compound 2c) is an inhibitor of GPX4, with free radical scavenging activity (maximum scavenging rate is 72.52%) and anti-tumor proliferation activity in vitro. GPX4-IN-14 inhibits GPX4 protein, increases lipid peroxide levels and intracellular Reactive Oxygen Species (ROS) levels, thereby inducing ferroptosis and exerting anti-tumor proliferation effects .

HY-W704973

F-ara-EdU	DNA/RNA Synthesis	Cancer
F-ara-EdU is a low-toxic, highly stable probe for DNA synthesis that is used as a marker for cell proliferation and DNA replication by binding to DNA or RNA in cells. F-ara-EdU can also be used to detect the rate of DNA synthesis within cells, as well as to study the mechanisms of DNA repair and damage .

HY-172430S

Epaldeudomide	TNF Receptor	Cancer
Epaldeudomide (Compound A406) is the inhibitor for TNF-α (>50% inhibition rate at 100 nM). Epaldeudomide inhibits the proliferation of cancer cells MM.1S (IC₅₀ < 300 nM), WSU-DLCL-2 (IC₅₀ < 100 nM) and Rec-1 (IC₅₀ < 100 nM). Epaldeudomide exhibits antineoplastic activity .

HY-N3862

Erythrodiol 3-O-palmitate	Others	Cancer
Erythrodiol 3-O-palmitate is a natural product isolated from Dicranostigma leptopodum (Maxim) Fedde, Gentiana rhodantha Franch or Swertia kouitchensis. Erythrodiol 3-O-palmitate has antitumor activity, and inhibits the proliferation of K562 cells with the inhibition rate of 47% at 100 ug/mL .

HY-101989

Tubulin polymerization-IN-24	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-24 (compound HMBA) is a potent tubulin polymerization inhibitor. Tubulin polymerization-IN-24 inhibits MCF-7 cells proliferation. Tubulin polymerization-IN-24 induces apoptosis and cell cycle arrest at G2/M phase. Tubulin polymerization-IN-24 increase the GTP hydrolysis rate and inhibits microtubule assembly .

HY-139434

JMJD6-IN-1	Histone Demethylase	Cancer
JMJD6-IN-1 (Compound 1-3) is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. JMJD6-IN-1 inhibits MCF-7 and HCC4006 cell proliferation with IC₅₀s of 19.2 μM and 25.2 μM. JMJD6-IN-1 can be used for research of cancers .

HY-P99901

Sibeprenlimab VIS649	SARS-CoV	Inflammation/Immunology Cancer
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .

HY-P10617

Salusin-β	Endogenous Metabolite	Cardiovascular Disease
Salusin-β is an endogenous bioactive peptide with significant hemodynamic and mitogenic activity. Salusin-β can stimulate the proliferation of quiescent vascular smooth muscle cells (VSMCs) and fibroblasts, leading to a rapid and significant decrease in blood pressure and heart rate. In addition, Salusin-β can stimulate the release of arginine vasopressin from the pituitary gland in rats. This makes Salusin-β have important application potential in cardiovascular disease research .

HY-144825

Chol-CTPP	Apoptosis Reactive Oxygen Species	Cancer
Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function .

HY-162787

Adenosine receptor antagonist 5	Adenosine Receptor	Cancer
Adenosine receptor antagonist 5 (Compound 39) is a selective antagonist for human adenosine A3 receptor (hA3R) with K_i of 12 nM. Adenosine receptor antagonist 5 inhibits IB-MECA (HY-13591)-induced cAMP accumulation in NCI-H1792 cell, inhibits the proliferation of cancer cell LK-2 and NCI-H1792. Adenosine receptor antagonist 5 exhibits a fast metabolic rate in human liver microsomes .

HY-P10490

(D-His(Bzl)6)-LHRH (1-7) free acid	Drug Derivative GnRH Receptor	Others Cancer
(D-His(Bzl)6)-LHRH (1-7) free acid is a synthetic peptide compound that is a derivative of luteinizing hormone-releasing hormone (LHRH). (D-His(Bzl)6)-LHRH (1-7) free acid enhances its stability and biological activity by introducing unnatural amino acid residues at specific positions of the LHRH molecule. This modification can improve the drug's performance in the body half-life, reducing the rate at which it is rapidly metabolized and cleared, thereby enhancing its efficacy in inhibiting cell proliferation .

HY-123187

AS2553627	JAK	Cardiovascular Disease
AS2553627 is a type of JAK inhibitor, with IC₅₀ values of 0.46, 0.30, 0.14, and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively. AS2553627 can inhibit the proliferation of human and rat T cells stimulated by IL-2, with IC₅₀ values of 2.4 and 4.3 nM, respectively. AS2553627 can reduce cardiac allograft vasculopathy and fibrosis in a rat heart transplant model, effectively extending survival rates. AS2553627 can be used to prevent acute and chronic rejection in heart transplants .

HY-170525

CD73-IN-19	CD73	Inflammation/Immunology
CD73-IN-19 (Compound 4ab) is a CD73 inhibitor (with a 44% inhibition rate of CD73 enzymatic activity at 100 μM). CD73-IN-19 (at 10 μM and 100 μM) can completely antagonize the blockade of T cell proliferation induced by TCR (T cell receptor) triggering (which is induced by CD73 activity), and it can also inhibit the hA2A receptor activity in HEK-293 cells (K_i is 3.31 μM). CD73-IN-19 holds promise for research in the field of immune diseases .

HY-158138

TOPOI/PARP-1-IN-1	PARP Topoisomerase Apoptosis	Cancer
TOPOI/PARP-1-IN-1 (Compound B6) is an orally active, low cytotoxic TOPOI/PARP dual inhibitor with an IC₅₀ value of 0.09 μM for PARP1. TOPOI/PARP-1-IN-1 can effectively inhibit the proliferation and migration of cancer cells. TOPOI/PARP-1-IN-1 also causes cell cycle arrest in the G0/G1 phase and induces apoptosis. The tumor growth inhibition rate (TGI) of TOPOI/PARP-1-IN-1 in mice is 75.4% .

HY-161641

Tubulin polymerization-IN-62	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-62 (Compound 14b) is an inhibitor for microtubule polymerization (IC₅₀ is 7.5 μM) and a degrader for α- and β-tubulin. Tubulin polymerization-IN-62 inhibits proliferation of cancer cells MCF-7, A549 and HCT-116, with IC₅₀ of 32, 60 and 29 nM, respectively. Tubulin polymerization-IN-62 arrests the cell cycle at G2/M phase, inhibits the migration of MCF-7. Tubulin polymerization-IN-62 exhibits antitumor efficacy with a tumor growth inhibition rate (TGI) of 74.27% in 4T1 homograft mouse model .

HY-152293

EVT801	VEGFR ERK	Cancer
EVT801 is an orally active and selective inhibitor of VEGFR-3 (IC₅₀=11 nM), which has antitumor effects. EVT801 inhibits not only VEGF-C-induced human endothelial cell proliferation, but also tumor (lymphatic) angiogenesis in tumor mouse models. EVT801 can reduce tumor hypoxia, immunosuppressive cytokines (CCL4, CCL5) and myeloid derived suppressor cells (MDSC) production. EVT801 has synergistic effect with immune checkpoint therapy (ICT), which improves ICT response rate and has better inhibitory effect on cancer mouse models . EVT801 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-111137

Puquitinib XC-302 free base	Akt	Cancer
Puquitinib (XC-302 free base) is a multi-target inhibitor with the activity of inducing autophagy in nasopharyngeal carcinoma cells by inhibiting the PI3K/AKT/mTOR signaling pathway. Puquitinib was able to inhibit the proliferation of CNE-2 cells, showing a dose-dependent antiproliferative effect. Puquitinib induced the formation of autophagosomes and autolysosomes in CNE-2 cells, which were observed by fluorescence microscopy and electron microscopy. Puquitinib promoted the formation of LC3-II and increased the expression of beclin 1, while reducing the level of p62. Puquitinib inhibited the PI3K/AKT/mTOR pathway by reducing the expression of p-AKT and p-mTOR. Puquitinib also induced apoptosis in CNE-2 cells, and when autophagy was inhibited, the apoptosis rate was reduced, which means that autophagy may interact with apoptosis to induce cell death .

Cat. No.	Product Name

HY-L201

Cell Proliferation Compound Library	2,467 compounds
Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others. MCE collects 2,467 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

Cell Proliferation Compound Library

2,467 compounds

Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.

MCE collects 2,467 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

Cat. No.	Product Name	Target	Research Area